DURECT began life in 1998 dedicated to exploiting the benefits of enhanced drug delivery. Our goal was to optimize the physical, pharmacokinetic, and pharmacodynamic properties of approved active agents in ways that would solve significant clinical problems. In recent years, we have built upon this significant legacy, expanding our reach to encompass the development of a family of endogenous molecules that are entirely new to pharmaceutical research and that show remarkable promise in a number of important therapeutic areas.

Whether taking aim at improved drug formulations or bringing to market therapies based on completely novel molecules and avenues of research, the men and women of DURECT strive to fulfill a fundamental promise to patients, physicians, corporate partners, and investors: create best-in-class pharmaceutical products with enduring value—measured most directly by their potential to make real, palpable differences in the lives of those who need them.

Show more
Cupertino, US
Size (employees)
98 (est)
Durect is headquartered in Cupertino, US
Report incorrect company information

Key People/Management at Durect

James E. Brown

James E. Brown

President and Chief Executive Officer
Matthew J. Hogan

Matthew J. Hogan

Matthew J. Hogan

Matthew J. Hogan

Chief Financial Officer
Felix Theeuwes

Felix Theeuwes


Durect Office Locations

Durect has an office in Cupertino
Cupertino, US (HQ)
DURECT 10260 Bubb Rd
Show all (1)
Report incorrect company information

Durect Financials and Metrics

Durect Financials

Durect's revenue was reported to be $49.17 m in FY, 2017

Revenue (FY, 2017)

49.2 m

Net income (FY, 2017)

(3.7 m)

EBIT (FY, 2017)

(2.2 m)

Market capitalization (20-Apr-2018)

306.5 m

Cash (31-Dec-2017)

29.4 m
Durect's current market capitalization is $306.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017


15.3 m19.4 m19.1 m14 m49.2 m

Revenue growth, %


Cost of goods sold

4.8 m5.7 m3.9 m5.3 m

Gross profit

10.5 m13.7 m15.2 m8.7 m
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017


7.8 m2.7 m3.6 m5.4 m29.4 m

Accounts Receivable

2.3 m2.1 m2.2 m1.2 m2.4 m


3.5 m3.6 m3.9 m3.8 m3.2 m

Current Assets

28.3 m39.5 m38.3 m32.4 m45.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(21.5 m)(22.1 m)(22.7 m)(34.5 m)(3.7 m)

Depreciation and Amortization

558 k601 k425 k416 k437 k


(681 k)(1.4 m)(579 k)(552 k)(140 k)

Accounts Payable

(1 m)285 k265 k800 k(566 k)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


3.2 m3.5 m4.6 m3.8 m3.8 m3.9 m4 m4 m4.2 m3.6 m3.5 m3.7 m

Accounts Payable

522 k1.2 m666 k1.1 m890 k654 k798 k994 k1.3 m1.5 m1.1 m1.8 m
USDY, 2017


488.4 k
Show all financial metrics
Report incorrect company information